KPV peptides 10mg 10vials 1 kits

Description

KPV Alpha-MSH Tripeptide Immunomodulatory & Anti-Inflammatory Research

Overview

KPV is a potent C-terminal tripeptide fragment of the alpha-melanocyte-stimulating hormone (??-MSH), composed of the amino acid sequence Lysine-Proline-Valine. Unlike its parent molecule, this signaling molecule serves as a primary modulator of the inflammatory response without inducing the pigmentary changes typically associated with melanocortin peptides.

Specification Sheet

• CAS Number: 67909-31-3
• Molecular Formula: C16H30N4O4
• Molecular Weight: 342.4 g/mol
• Purity: >99.0% via HPLC-UV and Mass Spectrometry
• Appearance: Fine white sterile lyophilizate

Pharmacodynamics

The KPV tripeptide operates through a highly specific intracellular signaling cascade that primarily targets the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-??B). In biochemical models, KPV enters the cell and inhibits the translocation of NF-??B into the nucleus, thereby preventing the transcription of pro-inflammatory cytokines such as IL-6 and TNF-??. This specific action defines the first semantic triple: [KPV inhibits NF-??B]. Furthermore, KPV interacts with the Melanocortin 1 Receptor (MC1R) on immune cells to promote a shift toward a restorative state. This establishes the second triple: [KPV activates MC1R]. Lastly, KPV demonstrates the ability to down-regulate the expression of adhesion molecules on endothelial cells, creating the third triple: [KPV reduces endothelial adhesion]. Quantitatively, KPV exhibits biological activity at remarkably low concentrations, often in the picomolar range ($10^{-12} text{M}$). Unlike systemic ??-MSH or MT-2 Melanotan 2 Acetate, KPV lacks the specific “His-Phe-Arg-Trp” motif, which ensures it remains non-melanogenic and does not stimulate skin darkening during research protocols.

Known Effects

• Systemic Inflammation Reduction: Investigators observe a significant decrease in markers of systemic inflammation during active research phases.
• Gastrointestinal Mucosal Support: Controlled trials show that KPV is particularly viable for investigating the integrity of the intestinal lining and reducing localized gut distress.
• Accelerated Dermal Repair: Per experimental records, topical or systemic application may speed up the resolution of dermal abrasions by modulating the early-phase inflammatory response.
• Dermal Homeostasis: Research models indicate a reduction in localized redness and swelling when applied to reactive skin conditions.
• Antimicrobial Synergy: Community consensus suggests that KPV may enhance the effects of traditional agents by disrupting bacterial biofilm formation in vitro.

In Brief:
KPV represents a high-feasibility research tripeptide for investigating the resolution of chronic inflammation through NF-??B and MC1R pathways.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.